Amendment: SEC Form SC 13G/A filed by CryoPort Inc.
$CYRX
Biotechnology: Pharmaceutical Preparations
Health Care
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/6/2025 | Sector Weight → Overweight | KeyBanc Capital Markets | |
| 8/6/2025 | $16.00 | Market Perform → Outperform | Leerink Partners |
| 7/22/2025 | $13.00 | Overweight | Stephens |
| 3/24/2025 | $10.00 | Neutral → Buy | UBS |
| 12/19/2024 | $11.00 | Buy | Guggenheim |
| 12/19/2024 | $11.00 | Buy | Canaccord Genuity |
| 8/7/2024 | $20.00 → $8.00 | Buy → Hold | Jefferies |
| 7/31/2024 | $19.00 → $15.00 | Neutral → Buy | B. Riley Securities |
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th
NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd
Self-Sustaining Fusion® 800 Series Cryogenic Freezer Delivers High-Capacity Storage, Flexibility, and Cost Benefits in Limited Space Environments NASHVILLE, Tenn., Feb. 11, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced the launch of the MVE Fusion® 800 Series, the next evolution of MVE Biological Solutions' patented, award-winning Fusion technology. This self-sustaining cryogenic freezer eliminates the need for a continuous liquid nitrogen (LN₂) supply, delivering exceptional reliability, safety, and sustainability in a compact footprint designe
144 - Cryoport, Inc. (0001124524) (Subject)
10-K - Cryoport, Inc. (0001124524) (Filer)
8-K - Cryoport, Inc. (0001124524) (Filer)
KeyBanc Capital Markets upgraded Cryoport from Sector Weight to Overweight
Leerink Partners upgraded Cryoport from Market Perform to Outperform and set a new price target of $16.00
Stephens resumed coverage of Cryoport with a rating of Overweight and set a new price target of $13.00
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
4 - Cryoport, Inc. (0001124524) (Issuer)
SC 13G - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
SC 13G/A - Cryoport, Inc. (0001124524) (Subject)
FY 2025 revenue increased to $176.2 million, exceeding the high end of previous guidanceLife Sciences Services revenue grew 18% year-over-year in FY 2025, including a 22% rise in BioStorage/BioServices revenue Commercial cell and gene therapy revenue increased 29% year-over-year to $33.4 million in FY 2025Supported a record 760 global clinical trials and 20 commercially approved therapies as of December 31, 2025Full-year 2026 revenue guidance of $190 million to $194 million (8%-10% growth y-o-y)NASHVILLE, Tenn., March 3, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of integrated temperature-controlled supply chain solutions for th
NASHVILLE, Tenn., Feb. 17, 2026 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced that the Company will report financial results for the fourth quarter and year ended December 31, 2025 on Tuesday, March 3, 2026 after U.S. markets close. In addition to the earnings release, a document titled "Cryoport Fourth Quarter and Full Year 2025 in Review", providing a review of Cryoport's financial and operational performance and a general business upd
Third quarter revenue increased 15% year-over-year to $44.2 millionCommercial Cell & Gene Therapy revenue increased 36% year-over-year to $8.3 millionLife Sciences Services revenue grew 16% year-over-year, including a 21% rise in BioStorage/BioServices revenue Life Sciences Products revenue grew 15% year-over-yearCompany updates full year 2025 revenue guidance of $170 to $174 millionNASHVILLE, Tenn., Nov. 4, 2025 /PRNewswire/ -- Cryoport, Inc. (NASDAQ:CYRX) ("Cryoport" or the "Company"), a leading global provider of temperature-controlled supply chain solutions for the life sciences, today announced financial results for its third quarter (Q3) and first nine months (9M) of 2025. Provided in
Cryoport's CRYOGENE will provide Moffitt with state-of-the-art biorepository services TAMPA, Fla. and NASHVILLE, Tenn., Jan. 14, 2025 /PRNewswire/ -- Moffitt Cancer Center, a leading National Cancer Institute-designated comprehensive cancer center, through its wholly owned subsidiary Speros FL, a 775-acre global innovation life sciences campus, and Cryoport, Inc. (NASDAQ:CYRX), a global leader in supply chain solutions for the life sciences industry, today announced a strategic collaboration that will provide CRYOGENE's state-of-the-art biorepository services to Speros in Pasco County, Florida. Cryoport's CRYOGENE business unit is a leading biorepository for the life sciences industry that i
NASHVILLE, Tenn., March 3, 2021 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences industry, today announced its Board of Directors has elected Linda Baddour as a member of the Board, effective March 15, 2021. Linda Baddour is a senior executive with over twenty years of experience in healthcare, life sciences and pharmaceuticals. "Our corporate governance underpins all that we do at Cryoport and we are delighted to strengthen our Board as we leverage our newly expanded global footprint and advanced temperature-controlled supply chain platform to spur our growth," said Jerrell She
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. ("BriaCell" or the "Company") (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, is pleased to announce that Mr. Martin Schmieg has rejoined the Company as a member of its Board of Directors. Having previously served as a member of BriaCell’s Board of Directors from 2016 to 2019, Mr. Schmieg is a “C” level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries with 40 years of business experience. He currently serves as Co-Founder and CEO of ClearIt, L